<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BioTech (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">BioTech (Basel)</journal-id><journal-id journal-id-type="publisher-id">biotech</journal-id><journal-title-group><journal-title>BioTech</journal-title></journal-title-group><issn pub-type="epub">2673-6284</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407486</article-id><article-id pub-id-type="pmc">PMC12101427</article-id>
<article-id pub-id-type="doi">10.3390/biotech14020031</article-id><article-id pub-id-type="publisher-id">biotech-14-00031</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Vaginal Microbiota Patterns Associated with Yeast Infection in Mexican Women, a Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pineda-D&#x000ed;az</surname><given-names>Janet</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref><xref rid="fn1-biotech-14-00031" ref-type="author-notes">&#x02020;</xref><xref rid="fn3-biotech-14-00031" ref-type="author-notes">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Miranda-Brito</surname><given-names>Carolina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref><xref rid="fn1-biotech-14-00031" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8860-1702</contrib-id><name><surname>Ju&#x000e1;rez-Castel&#x000e1;n</surname><given-names>Carmen Josefina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Pi&#x000f1;a-Escobedo</surname><given-names>Alberto</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-0519-4559</contrib-id><name><surname>L&#x000e1;zaro-P&#x000e9;rez</surname><given-names>Noem&#x000ed; del Socorro</given-names></name><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-3771-0087</contrib-id><name><surname>de la Cruz-Mungu&#x000ed;a</surname><given-names>Alejandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ram&#x000ed;rez-S&#x000e1;nchez</surname><given-names>Daniela</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref><xref rid="fn2-biotech-14-00031" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000f3;mez-Meraz</surname><given-names>Yuliana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-biotech-14-00031" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5713-0776</contrib-id><name><surname>V&#x000e9;lez-Ixta</surname><given-names>Juan Manuel</given-names></name><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref><xref rid="fn4-biotech-14-00031" ref-type="author-notes">&#x02016;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0595-3711</contrib-id><name><surname>Garc&#x000ed;a-Mena</surname><given-names>Jaime</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-biotech-14-00031" ref-type="aff">1</xref><xref rid="c1-biotech-14-00031" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Caparros-Martin</surname><given-names>Jose</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-biotech-14-00031"><label>1</label>Departamento de Gen&#x000e9;tica y Biolog&#x000ed;a Molecular, Cinvestav, Av. Instituto Polit&#x000e9;cnico Nacional 2508, Mexico City 07360, Mexico; <email>jpineda@cinvestav.mx</email> (J.P.-D.); <email>cmiranda@cinvestav.mx</email> (C.M.-B.); <email>carmen.juarez@cinvestav.mx</email> (C.J.J.-C.); <email>apinae@cinvestav.mx</email> (A.P.-E.); <email>noemi.lazaro@cinvestav.mx</email> (N.d.S.L.-P.); <email>alejandra.delacruz@cinvestav.mx</email> (A.d.l.C.-M.); <email>danielaramireza23@gmail.com</email> (D.R.-S.); <email>juan.velez@cinvestav.mx</email> (J.M.V.-I.)</aff><aff id="af2-biotech-14-00031"><label>2</label>Ginecolog&#x000ed;a y Obstetricia, Centro M&#x000e9;dico ABC Santa Fe, Av. Carlos Graef Fern&#x000e1;ndez 154, Mexico City 05300, Mexico; <email>ygm85@hotmail.com</email></aff><author-notes><corresp id="c1-biotech-14-00031"><label>*</label>Correspondence: <email>jgmena@cinvestav.mx</email></corresp><fn id="fn1-biotech-14-00031"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-biotech-14-00031"><label>&#x02021;</label><p>Current address: Department of Molecular Biology, Max Planck Institute for Biology T&#x000fc;bingen. Max-Planck-Ring 5, 72076 T&#x000fc;bingen, Germany.</p></fn><fn id="fn3-biotech-14-00031"><label>&#x000a7;</label><p>Current address: Departamento de Patolog&#x000ed;a Quir&#x000fa;rgica y Molecular, Centro M&#x000e9;dico ABC Observatorio, Mexico City 01120, Mexico.</p></fn><fn id="fn4-biotech-14-00031"><label>&#x02016;</label><p>Department of Pediatrics, Cumming School of Medicine, University of Calgary, 2500 University Drive NW, Calgary Alberta T2N 1N4, Canada.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>14</volume><issue>2</issue><elocation-id>31</elocation-id><history><date date-type="received"><day>11</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Recurrent vulvovaginal candidiasis (RVVC) is a common condition that affects women of reproductive age. The etiology of RVVC remains largely unknown, but it is believed to be associated with changes in vaginal microbiota composition. This study investigates the vaginal microbiota in 57 women with RVVC and 38 healthy controls. Bacterial DNA was analyzed using high-throughput 16S rRNA gene sequencing, and <italic toggle="yes">Candida</italic> and <italic toggle="yes">Saccharomyces</italic> species were determined by PCR. RVVC cases had a higher prevalence of <italic toggle="yes">Nakaseomyses glabratus</italic> (former <italic toggle="yes">Candida glabrata</italic>) compared to controls. Alpha diversity metrics were similar between groups, but beta diversity analysis revealed significant differences in vaginal microbiota composition. The Firmicutes abundance was altered in RVVC cases, with genus <italic toggle="yes">Bifidobacterium</italic> and phylum Actinobacteriota being more abundant than in the controls. At the genus level, <italic toggle="yes">Lactobacillus</italic> dominated controls using antibiotics, while <italic toggle="yes">Bifidobacterium</italic> was higher in cases with no antibiotic intake. Our study provides evidence that <italic toggle="yes">Nakaseomyses glabratus</italic> (former <italic toggle="yes">Candida glabrata</italic>) is a significant pathogen in RVVC, while <italic toggle="yes">Candida albicans</italic> was more prevalent in healthy women. The vaginal microbiota composition differs significantly between the two groups, with distinct patterns of bacterial abundance and changes in Firmicutes abundance.</p></abstract><kwd-group><kwd>RVVC</kwd><kwd><italic toggle="yes">Candida albicans</italic></kwd><kwd><italic toggle="yes">Nakaseomyses glabratus</italic></kwd><kwd><italic toggle="yes">Candida glabrata</italic></kwd><kwd><italic toggle="yes">Saccharomyces cerevisiae</italic></kwd><kwd>vaginal microbiota</kwd><kwd>16S rRNA</kwd></kwd-group><funding-group><award-group><funding-source>Secretar&#x000ed;a de Ciencia, Humanidades, Tecnolog&#x000ed;a e Innovaci&#x000f3;n (SECIHTI)</funding-source><award-id>CONACYT-163235</award-id></award-group><award-group><funding-source>Programa Presupuestario F003-Ciencia de Frontera 2019 &#x0201c;Estudio de la v&#x000ed;a Tracto-Digestivo-Materno Leche-Materna Tracto-digestivo-neonato, una aproximaci&#x000f3;n &#x000f3;mica&#x0201d;</funding-source><award-id>CONACYT FORDECYT-PRONACES/6669/2020</award-id></award-group><award-group><funding-source>Convocatoria 2019, Proyectos Cient&#x000ed;ficos, Tecnol&#x000f3;gicos y/o de Innovaci&#x000f3;n para la atenci&#x000f3;n a problemas espec&#x000ed;ficos de la Ciudad de M&#x000e9;xico relacionados con la investigaci&#x000f3;n y atenci&#x000f3;n de enfermedades cr&#x000f3;nicas no transmisibles (ECNT)</funding-source><award-id>SECTEI/249/2019&#x02014;CM-SECTEI/109/2020&#x02014;CM-SECTEI/124/2021</award-id></award-group><funding-statement>This work was supported by Cinvestav, Secretar&#x000ed;a de Ciencia, Humanidades, Tecnolog&#x000ed;a e Innovaci&#x000f3;n (SECIHTI): CONACYT-163235, Laboratorio de Referencia y Apoyo para la Caracterizaci&#x000f3;n de Genomas, Transcriptomas y Microbiomas en la Unidad Zacatenco del Cinvestav; by CONACYT FORDECYT-PRONACES/6669/2020_Programa Presupuestario F003-Ciencia de Frontera 2019 &#x0201c;Estudio de la v&#x000ed;a Tracto-Digestivo-Materno Leche-Materna Tracto-digestivo-neonato, una aproximaci&#x000f3;n &#x000f3;mica&#x0201d;, and by SECTEI/249/2019&#x02014;CM-SECTEI/109/2020&#x02014;CM-SECTEI/124/2021, Convocatoria 2019, Proyectos Cient&#x000ed;ficos, Tecnol&#x000f3;gicos y/o de Innovaci&#x000f3;n para la atenci&#x000f3;n a problemas espec&#x000ed;ficos de la Ciudad de M&#x000e9;xico relacionados con la investigaci&#x000f3;n y atenci&#x000f3;n de enfermedades cr&#x000f3;nicas no transmisibles (ECNT). The funding body was not involved in study design; collection, management, analysis, and interpretation of data; or the decision to submit for publication.</funding-statement></funding-group></article-meta><notes notes-type="Key Contribution"><title>Key Contribution</title><p>The yeast <italic toggle="yes">Nakaseomyses glabratus</italic> (former <italic toggle="yes">Candida glabrata</italic>) was more abundant in all cases of recurrent vulvovaginal candidiasis, while <italic toggle="yes">C. albicans</italic> was more prevalent among healthy women. The presence of <italic toggle="yes">N. glabratus</italic> was associated with significant changes in the bacterial microbiota diversity with an increased abundance of Bifidobacterium (Actinobacteriota phylum), while the controls exhibited a larger abundance of Lactobacillus (Firmicutes phylum). This adds important information about the perturbation of the vaginal microbial ecology under stress conditions due to yeast pathogens&#x02019; presence.</p></notes></front><body><sec sec-type="intro" id="sec1-biotech-14-00031"><title>1. Introduction</title><p>The human body is inhabited by many microorganisms, bacteria, archaea, and fungi, collectively known as microbiota [<xref rid="B1-biotech-14-00031" ref-type="bibr">1</xref>]. Among them, vaginal microbiota constitutes about 9% of total human microbiota and comprises a diverse array of beneficial microbes and opportunistic pathogens that inhabit the vaginal milieu [<xref rid="B2-biotech-14-00031" ref-type="bibr">2</xref>,<xref rid="B3-biotech-14-00031" ref-type="bibr">3</xref>]. The organisms that inhabit the vagina are dynamic and respond uniquely to various factors such as diet, exercise, medications, and diseases, which cause bacterial dysbiosis. This disruption increases the risk of contracting different urogenital microbial and fungal infections, which can be caused by sexually transmitted infections (STIs) or pelvic inflammatory disease (PID) [<xref rid="B2-biotech-14-00031" ref-type="bibr">2</xref>,<xref rid="B4-biotech-14-00031" ref-type="bibr">4</xref>].</p><p>Some of the characteristic symptoms of vaginal infections occurring in women of reproductive age are foul odor, burning, itching, and presence of discharge [<xref rid="B5-biotech-14-00031" ref-type="bibr">5</xref>]. In the case of pregnant women, this microbial ecosystem changes according to the maturation stages of the woman, for example, weeks after childbirth, maternal estrogen metabolism promotes the proliferation of various aerobic and anaerobic bacteria due to mucosa thinning, an increase in vaginal pH, and a reduction in the glycogen substrate [<xref rid="B6-biotech-14-00031" ref-type="bibr">6</xref>]. Lactobacillus of genera <italic toggle="yes">L. jensenii</italic>, <italic toggle="yes">L. inerss</italic>, <italic toggle="yes">L. gasseri</italic>, <italic toggle="yes">L. crispatus</italic>, and <italic toggle="yes">Gardnerella vaginalis</italic> mainly dominate the vaginal microbial community of healthy women in reproductive age [<xref rid="B1-biotech-14-00031" ref-type="bibr">1</xref>,<xref rid="B2-biotech-14-00031" ref-type="bibr">2</xref>], and in the last trimester of pregnancy [<xref rid="B7-biotech-14-00031" ref-type="bibr">7</xref>]. These microorganisms prevent the invasion of pathogens, keeping the population in control. Previous work focusing on Mexican women using PCR and denaturing gradient gel electrophoresis (PCR-DGGE) reported bacterial communities in the vaginal tract of Mexican women during pregnancy, identifying 21 microorganism species, with 62.5% belonging to the genus <italic toggle="yes">Lactobacillus</italic>, 8.5% to non-cultivated <italic toggle="yes">Ureaplasma</italic>, 6.7% to BVAB1, and 3.0% to <italic toggle="yes">Gemella bergeriae</italic> [<xref rid="B8-biotech-14-00031" ref-type="bibr">8</xref>].</p><p>In the case of fungi in humans, members of the fungal genera <italic toggle="yes">Candida</italic> are commonly found on the skin and mucous membranes, producing in some cases an opportunistic vaginal infection called candidiasis. <italic toggle="yes">Candida albicans</italic> is one of the leading agents associated with vulvovaginal candidiasis (VVC), a multifactorial infectious disease of the female reproductive tract that predominates during fertile years in women [<xref rid="B9-biotech-14-00031" ref-type="bibr">9</xref>]. Some studies report that microbial diversity characterized by low <italic toggle="yes">Lactobacillus</italic> abundance is associated with low levels of inflammation, and high non-<italic toggle="yes">Lactobacillus</italic> dominated diversity (dysbiosis) is associated with increased risk of infection and obstetric complications [<xref rid="B1-biotech-14-00031" ref-type="bibr">1</xref>,<xref rid="B10-biotech-14-00031" ref-type="bibr">10</xref>].</p><p>Furthermore, fungi, especially yeast <italic toggle="yes">Candida</italic>, are found in vaginal mucosa as symbionts, forming a complex vaginal ecosystem with other bacteria. Fungi play diverse roles, such as lowering vaginal pH, producing bioactive compounds, competing for nutrients, adhesion sites, and regulating host immune responses [<xref rid="B4-biotech-14-00031" ref-type="bibr">4</xref>,<xref rid="B11-biotech-14-00031" ref-type="bibr">11</xref>]. It is reported that an overgrowth of <italic toggle="yes">Candida</italic>, specifically <italic toggle="yes">C. albicans</italic>, characterizes VVC, one of the most common vaginal infections, and inflammation. This fungus is one of the most abundant species in premenopausal women, pregnant women, and women with acute VVC [<xref rid="B4-biotech-14-00031" ref-type="bibr">4</xref>]. The haploid fungi <italic toggle="yes">Nakaseomyses glabratus</italic> (former <italic toggle="yes">Candida glabrata</italic>) may be a regular component of the epithelial microbiota of the skin, oral cavity, gastrointestinal, and urogenital tract. Also known as an opportunistic pathogen, it is associated with different vertebrate microbiotas. This fungus is reported in Europe and North America as the second cause of candidiasis and has recently been reclassified as <italic toggle="yes">Nakaseomyses glabratus</italic> [<xref rid="B12-biotech-14-00031" ref-type="bibr">12</xref>,<xref rid="B13-biotech-14-00031" ref-type="bibr">13</xref>].</p><p>The purpose of this work was to characterize vaginal bacterial diversity in conditions of yeast infection in a sample of Mexican women to identify taxa signatures with a potential association with the presence of <italic toggle="yes">Nakaseomyses glabratus</italic> (former <italic toggle="yes">Candida glabrata</italic>) and or <italic toggle="yes">Candida albicans.</italic></p></sec><sec id="sec2-biotech-14-00031"><title>2. Materials and Methods</title><sec id="sec2dot1-biotech-14-00031"><title>2.1. Experimental Design</title><p>This study recruited Mexican women aged 18&#x02013;45 from gynecological consultations at the ABC Medical Center in Mexico City (19&#x000b0;23&#x02032;57.4026&#x02033; N 99&#x000b0;11&#x02032;47.57136&#x02033; W), using a convenient sampling approach. Participants were divided into two groups. Cases were women with recurrent vulvovaginal candidiasis (RVVC), having at least four episodes in the past 12 months, while controls were healthy women attending routine annual Papanicolaou test (pap smear test) consultations, without a history of recurrent vaginitis. Inclusion criteria for both groups required abstinence from sexual activity for 48 h, no menstruation at the time of sample collection, and no diagnosis of diabetes mellitus, obesity, or autoimmune diseases. Cases were additionally required to have a history of RVVC, while controls were limited to a history of one or fewer vaginitis episodes over their lifetime. Exclusion criteria included menstruation during sample collection or declining to participate. Controls were excluded if they had symptoms of vaginitis within the past six months or a history of more than one vaginitis episode diagnosed as vulvovaginal candidiasis. Cases were excluded if they did not meet the number of RVVC episodes or the specified age range. All participants provided informed consent following the 2013 Declaration of Helsinki after receiving a detailed explanation of the study. The protocol was approved by the Committee of Research and the Ethics in Research Committee of the ABC Medical Center (Project identification code: 2016-06-23). Samples were collected from June 2016 to May 2017.</p></sec><sec id="sec2dot2-biotech-14-00031"><title>2.2. Vaginal Swab Sampling</title><p>Participants were positioned on a gynecological examination table with stirrups, and a vaginal speculum was inserted for sample collection. Cervicovaginal mucus was collected using Catch-All&#x02122; Sample Collection Swabs (Epicentre, Illumina, San Diego, CA, USA, Cat# QEC89100) from the vaginal fornix. The vaginal pH was measured using Hydrion pH test strips (MicroEssential, Brooklyn, NewYork, NY, USA, Cat#165/1-12). The swab trimmed to fit was then placed in a 2 mL tube containing sterile PBS solution pH 7.0 and stored at 4 &#x000b0;C until DNA extraction.</p></sec><sec id="sec2dot3-biotech-14-00031"><title>2.3. DNA Extraction from Vaginal Swab Samples</title><p>DNA was extracted from vaginal swab samples using the GeneAll Exgene Stool SV Kit (Gene All, Songpa-gu, Seoul, Korea, Cat#115-150). The samples were centrifuged for 5 min at 3800&#x000d7; <italic toggle="yes">g</italic>, and the supernatant was discarded. The pellet was resuspended in 1.0 mL of PBS buffer pH 7.0, vortexed for 1 min, and incubated at room temperature for 30 s. After centrifugation at maximum speed for 2 min, the supernatant was discarded. The pellet was resuspended in 1.3 mL of Buffer FL, incubated for 5 min at room temperature, and centrifuged at &#x02265;10,000&#x000d7; <italic toggle="yes">g</italic> for 5 min. The supernatant was transferred to an EzPass filter column, centrifuged, and eluted into a clean 1.5 mL tube with 100 &#x000b5;L of Buffer EB. After further purification steps involving Buffer PB and Buffer NW, the final DNA elution was performed with 50 &#x000b5;L of Buffer EB. DNA integrity and concentration were verified using a Nanodrop 2000 spectrophotometer (Thermo Scientific; Waltham, MA, USA, Cat#ND-2000) and 0.5% agarose gel electrophoresis.</p></sec><sec id="sec2dot4-biotech-14-00031"><title>2.4. 16S rRNA Gene Library Preparation</title><p>The V3 polymorphic region of bacterial 16S rRNA gene, ~281 bp in length, was amplified using primer V3-341F series (positions 340&#x02013;356 of <italic toggle="yes">Escherichia coli</italic> 16S rDNA molecule <italic toggle="yes">rrnB</italic> GenBank accession number J01859.1), containing different 12 pb Golay barcode, and antisense primer V3-518R (complementary to positions 517&#x02013;533) (<xref rid="app1-biotech-14-00031" ref-type="app">Table S1</xref>). The PCR was carried out in the GeneAmp PCR System 2700 Thermal Cycler (Applied Biosystems, ThermoFisher Scientific, Waltham, MA, USA), and the program was 5 min 95 &#x000b0;C; 25 cycles [15 s, 94 &#x000b0;C; 15 s, 62 &#x000b0;C; 15 s, 72 &#x000b0;C] followed by an extension of 10 min at 72 &#x000b0;C [<xref rid="B14-biotech-14-00031" ref-type="bibr">14</xref>].</p></sec><sec id="sec2dot5-biotech-14-00031"><title>2.5. High-Throughput DNA Semiconductor Sequencing</title><p>Equal concentrations of amplicons were pooled and purified, subsequently sequenced as previously reported [<xref rid="B14-biotech-14-00031" ref-type="bibr">14</xref>]. DNA library concentration and final fragment size were measured with the 2100 Bioanalyzer Instrument fragment analyzer (Agilent Technologies, Santa Clara, CA, USA), and the average library size obtained was 263 bp. Emulsion PCR was carried out using Ion OneTouchTM 200 Template Kit v2 DL (Life Technologies, Carlsbad, CA, USA). Amplicon enrichment with ionic beads was carried out using Ion OneTouch ES (Life Technologies, Carlsbad, CA, USA). The Ion 318 Kit V2 chip (Cat. 4488146, Life Technologies, Carlsbad, CA, USA) and the Ion Torrent PGM system were used for sequencing. The reads were filtered using PGM software to eliminate polyclonal (homopolymers &#x0003e; 6) and low-quality sequences (quality score &#x02264; 20).</p></sec><sec id="sec2dot6-biotech-14-00031"><title>2.6. Yeast Identification by PCR Targeting ITS1 and ITS2 and MEX67 Gene</title><p>To characterize the etiology of RVVC in samples from the participants, PCR reactions were performed using species-specific primers for <italic toggle="yes">C. albicans</italic> and <italic toggle="yes">N. glabratus</italic> (former <italic toggle="yes">C. glabrata</italic>), targeting the ITS1 and ITS2 of <italic toggle="yes">C. albicans</italic> and <italic toggle="yes">C. glabrata</italic>, respectively (<xref rid="app1-biotech-14-00031" ref-type="app">Table S2</xref>) [<xref rid="B13-biotech-14-00031" ref-type="bibr">13</xref>,<xref rid="B15-biotech-14-00031" ref-type="bibr">15</xref>]. Primers for <italic toggle="yes">S. cerevisiae</italic> targeting the nuclear export MEX67 gene [<xref rid="B16-biotech-14-00031" ref-type="bibr">16</xref>] (<xref rid="app1-biotech-14-00031" ref-type="app">Table S2</xref>) were included due to the potential involvement of this yeast in vulvovaginitis, which clinically resembles <italic toggle="yes">Candida</italic> infections. For ITS, the PCR program followed the initial denaturation step at 96 &#x000b0;C for 5 min, followed by 30 cycles [30 s, 94 &#x000b0;C, 30 s, 58 &#x000b0;C, and 30 s, 72 &#x000b0;C], a final extension at 72 &#x000b0;C for 15 min, cooling to 10 &#x000b0;C for 10 min; for MEX67 initial denaturation step at 94 &#x000b0;C for 5 min, followed by 30 cycles [60 s, 94 &#x000b0;C, 60 s, 58 &#x000b0;C, and 60 s, 72 &#x000b0;C], and a final extension at 72 &#x000b0;C for 5 min, cooling to 10 &#x000b0;C for 5 min. Positive controls included <italic toggle="yes">C. albicans</italic> ATCC, <italic toggle="yes">C. glabrata</italic> CBS138, and <italic toggle="yes">S. cerevisiae</italic> S2886, and negative controls used reaction mixtures without DNA templates. Amplicons of ~273 bp, 423 bp, and 150 bp were fractionated in 2.0% agarose gel electrophoresis stained with Midori Green Advanced dye(Nippon Genetics<sup>&#x000ae;</sup>, Dueren, Germany), and products were visualized using the Molecular Imager Gel Doc XR system Mod. Universal Hood II (Bio-Rad, Hercules, CA, USA, Cat#8195). The three PCR products were cloned using the GeneJET PCR Cloning Kit (ThermoFisher Scientific, Waltham, MA, USA), and plasmid DNA was extracted for Sanger capillary sequencing with pJET1 primers [<xref rid="B15-biotech-14-00031" ref-type="bibr">15</xref>]. Resulting sequences were analyzed using VECTOR NTI Advance and BLAST alignments to verify species-specific diagnostic accuracy.</p></sec><sec id="sec2dot7-biotech-14-00031"><title>2.7. ASV Determination and Taxonomic Annotation</title><p>The FASTQ files were further processed and analyzed using QIIME 2022.2 [<xref rid="B17-biotech-14-00031" ref-type="bibr">17</xref>]. Amplicon Sequence Variants (ASVs) were determined with the QIIME dada2 denoise-single plugin, with sequence truncation at 238 nt. Taxonomic assignment was performed using the feature-classifier classify-consensus-blast plugin with a 99% percentage identity. The Greengenes 2 database was used for BLAST analysis (QIIME 2022.2) [<xref rid="B18-biotech-14-00031" ref-type="bibr">18</xref>].</p></sec><sec id="sec2dot8-biotech-14-00031"><title>2.8. Bioinformatic Analyses</title><p>The analyses were conducted with RStudio in R 4.2.0 [<xref rid="B19-biotech-14-00031" ref-type="bibr">19</xref>,<xref rid="B20-biotech-14-00031" ref-type="bibr">20</xref>]. The following packages were employed for relative abundance, diversity and differential analyses: phyloseq 1.4.0 [<xref rid="B21-biotech-14-00031" ref-type="bibr">21</xref>], DESeq2 1.3.6 [<xref rid="B22-biotech-14-00031" ref-type="bibr">22</xref>], and ALDEx2 1.36.0; qiime2R [<xref rid="B23-biotech-14-00031" ref-type="bibr">23</xref>] to import the qiime artifacts [<xref rid="B24-biotech-14-00031" ref-type="bibr">24</xref>]; for alpha and beta diversity analyses vegan 2.6-2 [<xref rid="B25-biotech-14-00031" ref-type="bibr">25</xref>]; lefser 1.15.9 [<xref rid="B26-biotech-14-00031" ref-type="bibr">26</xref>] for discriminatory analyses; ComplexHeatmap 2.12.0 [<xref rid="B27-biotech-14-00031" ref-type="bibr">27</xref>] for heatmap elaboration; and tidyverse 1.3.1 [<xref rid="B28-biotech-14-00031" ref-type="bibr">28</xref>], dplyr 1.09, ggplot2 3.3.6, scales 1.2.0, ggpubr 0.4.4, and gridExtra 2.3 [<xref rid="B29-biotech-14-00031" ref-type="bibr">29</xref>] for graphical images.</p></sec></sec><sec sec-type="results" id="sec3-biotech-14-00031"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-biotech-14-00031"><title>3.1. Characteristics of Participants and Candida Prevalence in Vaginosis Cases vs. Controls</title><p>In this study, 38 controls and 57 cases met the inclusion criteria, of which 27 controls and 54 cases were successfully sequenced (<xref rid="app1-biotech-14-00031" ref-type="app">Table S3</xref>). No statistically significant differences were observed between groups regarding age, age of menarche, sexual life start, or vaginal pH, and other variables showed similar distribution between groups (<xref rid="app1-biotech-14-00031" ref-type="app">Figure S1</xref>). A subset of participants, 13 cases (30.95%), and 25 controls (43.86%) reported the use of antibiotics in the last three months, and this factor was considered in subsequent analyses. Additionally, PCR detection revealed significant differences in the prevalence of <italic toggle="yes">C. albicans</italic> (90% in controls vs. 36.17% in cases) and <italic toggle="yes">N. glabratus</italic> (0.0% controls vs. 97.87% cases) based on two-proportion z-tests (<xref rid="biotech-14-00031-f001" ref-type="fig">Figure 1</xref>C, <xref rid="biotech-14-00031-t001" ref-type="table">Table 1</xref>). On the other hand, <italic toggle="yes">S. cerevisiae</italic> showed a comparable abundance in both groups (90.0% controls vs. 95.74% cases).</p></sec><sec id="sec3dot2-biotech-14-00031"><title>3.2. Antibiotic Intake and Patient Condition Have a Small Effect on Beta Diversity</title><p>The sequencing data were processed as described in the <xref rid="sec2-biotech-14-00031" ref-type="sec">Section 2</xref>. For samples with low sequencing depth, re-sequencing was performed, and the resulting reads were combined by summation (<xref rid="app1-biotech-14-00031" ref-type="app">Figure S2</xref>). Both alpha and beta diversity metrics were analyzed to investigate the impact of antibiotic use and patient condition on global bacterial diversity. While alpha diversity appeared unaffected by these factors, beta diversity showed significant associations based on ADONIS tests. Weighted beta diversity was influenced primarily by patient condition (<italic toggle="yes">p</italic> = 0.042), whereas unweighted beta diversity was significantly associated with both patient condition (<italic toggle="yes">p</italic> = 0.012) and antibiotic use (<italic toggle="yes">p</italic> = 0.018). Despite these findings, the low <inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> values indicate a small effect (<xref rid="biotech-14-00031-f002" ref-type="fig">Figure 2</xref>). Additionally, sequencing depth was examined with antibiotic consumption to determine whether it contributed to reduced read counts, yet no evidence of such an effect was found (<xref rid="app1-biotech-14-00031" ref-type="app">Figure S3</xref>).</p></sec><sec id="sec3dot3-biotech-14-00031"><title>3.3. Vaginal Microbiota Composition Reflects RVVC Condition and Antibiotic Use</title><p>The composition of the vaginal microbiota was analyzed at both the phylum (<xref rid="biotech-14-00031-f003" ref-type="fig">Figure 3</xref>A) and genus levels (<xref rid="biotech-14-00031-f003" ref-type="fig">Figure 3</xref>B) to identify changes in key bacterial taxa across samples. Hierarchical clustering using weighted beta diversity was employed to compare taxa and assess similarities among bacterial communities in the groups. Samples were first grouped by antibiotic intake and subsequently by RVVC condition. Significant alterations were observed in the Firmicutes abundance, particularly between cases and controls. Cases without antibiotic use exhibited the highest abundance of Bacteroidota and Actinobacteriota phyla, whereas controls who had taken antibiotics were dominated by the Firmicutes_D phylum.</p><p>At the genus level, the members of the phylum Firmicutes_D were predominantly represented by <italic toggle="yes">Lactobacillus</italic>, which also dominated controls with antibiotic use. In contrast, cases without antibiotic intake showed a higher prevalence of <italic toggle="yes">Bifidobacterium</italic>, while <italic toggle="yes">Bacteroides_H</italic> was found only in controls who had not taken antibiotics. Notably, <italic toggle="yes">Fannyhessea</italic> was characteristic of cases without antibiotic use, whereas <italic toggle="yes">Sneathia</italic> was specific to cases with antibiotic use. Additionally, a marked increase in genus <italic toggle="yes">Prevotella</italic> was observed in cases where <italic toggle="yes">Lactobacillus</italic> was replaced by a diverse array of low-abundance taxa (&#x0003c;2%, grouped as &#x0201c;Other&#x0201d;). These findings highlight the dynamic shifts in microbial composition associated with antibiotic use and patient condition (<xref rid="biotech-14-00031-f003" ref-type="fig">Figure 3</xref>B).</p></sec><sec id="sec3dot4-biotech-14-00031"><title>3.4. Lactobacillus and Other Key Bacteria Are Associated with Healthy Vaginal Microbiota</title><p>Differential abundance analyses were performed to identify bacteria associated with vaginosis while accounting for antibiotic intake among participants. Two approaches were used: ALDEx2, with the formula &#x0201c;<inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>&#x0223c;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> antibiotic intake + RVVC condition&#x0201d;, and linear discriminant analysis (LEfSe), using RVVC as the class variable and antibiotic intake as the subclass. The results from ALDEx2 are presented in <xref rid="biotech-14-00031-f004" ref-type="fig">Figure 4</xref>A, with corresponding square root-transformed relative abundance values shown in <xref rid="biotech-14-00031-f004" ref-type="fig">Figure 4</xref>B. In the control group, <italic toggle="yes">Lactobacillus</italic> and an unassigned taxon were prominent. Interestingly, two distinct ASVs classified as <italic toggle="yes">Escherichia</italic>_710834 were identified in both the control and case groups.</p><p>LEfSe results are shown in <xref rid="biotech-14-00031-f004" ref-type="fig">Figure 4</xref>C, with the corresponding square root-transformed relative abundance values in <xref rid="biotech-14-00031-f004" ref-type="fig">Figure 4</xref>D. These findings corroborate the ALDEx2 results for <italic toggle="yes">Lactobacillus</italic>. In addition, <italic toggle="yes">Prevotella</italic>, <italic toggle="yes">Limosilactobacillus</italic>, <italic toggle="yes">Streptococcus</italic>, and <italic toggle="yes">Dialister</italic> were predominant in controls, whereas two distinct <italic toggle="yes">Escherichia</italic>_710834 ASVs, unassigned taxa, and <italic toggle="yes">Cutibacterium</italic> were characteristic of cases.</p></sec></sec><sec sec-type="discussion" id="sec4-biotech-14-00031"><title>4. Discussion</title><p>This work aims to characterize the vaginal microbiota of women suffering from RVVC. We found no differences between cases and control in women associated with metadata. For instance, no differences in vaginal pH were consistent with the disease diagnosis [<xref rid="B30-biotech-14-00031" ref-type="bibr">30</xref>]. The age prevalence in women is also consistent with the literature, which indicates that most episodes occur in the range from 19 to 35 years with lower prevalence rates after 50 years [<xref rid="B31-biotech-14-00031" ref-type="bibr">31</xref>]. In our sample, we observed a broader range between 20 to 50 years, with most cases around 35. Additionally, an association between RVVC incidence and new sexual partners is reported [<xref rid="B32-biotech-14-00031" ref-type="bibr">32</xref>]. In our work, there is a tendency among cases to have more sexual partners, but our results are not conclusive in this matter.</p><p>In this work, we detected by PCR <italic toggle="yes">N. glabratus</italic> (former <italic toggle="yes">C. glabrata</italic>) exclusive to RVVC cases, while <italic toggle="yes">C. albicans</italic> were found in higher proportion in the control group. Interestingly, some reports mention <italic toggle="yes">C. albicans</italic> as the major cause of infection, with 80&#x02013;95% of isolates identified as this species [<xref rid="B30-biotech-14-00031" ref-type="bibr">30</xref>]. Some other species, such as <italic toggle="yes">N. glabratus</italic> (formerly <italic toggle="yes">C. glabrata</italic>), <italic toggle="yes">Candida tropicalis</italic>, and <italic toggle="yes">Candida parapsilosis</italic>, are now frequently identified as human pathogens [<xref rid="B33-biotech-14-00031" ref-type="bibr">33</xref>]. Moreover, <italic toggle="yes">Candida</italic> spp. has been previously isolated from healthy women [<xref rid="B34-biotech-14-00031" ref-type="bibr">34</xref>,<xref rid="B35-biotech-14-00031" ref-type="bibr">35</xref>], and it has been reported that <italic toggle="yes">Candida</italic> infections are common and, in most cases, occur in non-symptomatic healthy individuals [<xref rid="B36-biotech-14-00031" ref-type="bibr">36</xref>]. Due to the contrasting results in this study, there might be an effect of the vaginal bacteria in our participants, which will be Fexplored further. It was also interesting, for the scope of this study, that a significant portion of participants in both groups reported the use of antibiotics. It has been reported that the intake of broad-spectrum antibiotics might reduce gut microbiota diversity [<xref rid="B37-biotech-14-00031" ref-type="bibr">37</xref>]. For this reason, we had to take antibiotic intake into account when evaluating the bacterial profile.</p><p>We found no major differences in alpha diversity between cases and controls in our work. However, a small effect was observed due to both antibiotic intake and RVVC. As mentioned before, it is expected that antibiotics have an impact on microbiota diversity, also in the context of vaginal microbiota, and in the long term might develop resistance and cause recurrent infections [<xref rid="B38-biotech-14-00031" ref-type="bibr">38</xref>]. Overall, the diversity in all groups was low, which is expected in the case of vaginal microbiota [<xref rid="B4-biotech-14-00031" ref-type="bibr">4</xref>], for instance, <italic toggle="yes">Clostridioides difficile</italic> infection in the gut could occur due to dysbiosis caused by antibiotics [<xref rid="B39-biotech-14-00031" ref-type="bibr">39</xref>]. Previous reports evaluating microbial diversity during RVVC conditions found major differences in alpha and beta diversity, with lower diversity in the cases [<xref rid="B40-biotech-14-00031" ref-type="bibr">40</xref>,<xref rid="B41-biotech-14-00031" ref-type="bibr">41</xref>].</p><p>Our relative abundance results indicate an increase in <italic toggle="yes">Bifidobacterium</italic> in association with RVVC, while antibiotic intake exhibited a mixed effect, increasing <italic toggle="yes">Bifidobacterium</italic> in controls and decreasing in the cases. In a previous study, a reduction in gut <italic toggle="yes">Bifidobacterium</italic> was observed in response to amoxicillin and azithromycin [<xref rid="B42-biotech-14-00031" ref-type="bibr">42</xref>]. <italic toggle="yes">Gardnerella vaginalis</italic> has been widely associated with vaginal infections [<xref rid="B43-biotech-14-00031" ref-type="bibr">43</xref>,<xref rid="B44-biotech-14-00031" ref-type="bibr">44</xref>], and recently, ATCC Genome Portal reclassified <italic toggle="yes">Gardnerella vaginalis</italic> as part of <italic toggle="yes">Bifidobacterium</italic> [<xref rid="B45-biotech-14-00031" ref-type="bibr">45</xref>]. In two previous works, studying women with bacterial vaginosis exposed to metronidazole or clindamycin, mixed effects in <italic toggle="yes">Gardnerella</italic> abundance were observed after the treatment, increasing in some women and decreasing in others [<xref rid="B46-biotech-14-00031" ref-type="bibr">46</xref>,<xref rid="B47-biotech-14-00031" ref-type="bibr">47</xref>]. Furthermore, we found <italic toggle="yes">Sneathia</italic> in cases where the participant consumed oral antibiotics. Previous work showed <italic toggle="yes">Sneathia</italic> was unchanged by antibiotic intake [<xref rid="B47-biotech-14-00031" ref-type="bibr">47</xref>]. There is sufficient evidence pointing to <italic toggle="yes">Sneathia</italic> as an emerging pathogen in female reproductive disease with adverse perinatal outcomes [<xref rid="B48-biotech-14-00031" ref-type="bibr">48</xref>].</p><p>Additionally, we identified <italic toggle="yes">Lactobacillus</italic> with ALDEx2 and LEFSE as characteristic of healthy women when comparing to RVVC. This is consistent with other works [<xref rid="B2-biotech-14-00031" ref-type="bibr">2</xref>,<xref rid="B49-biotech-14-00031" ref-type="bibr">49</xref>], which have linked <italic toggle="yes">Lactobacillus</italic> to a healthy vagina when studying bacterial vaginosis. Remarkably, we found different ASVs classified as <italic toggle="yes">Escherichia</italic> in our study, characterizing both cases and controls. Another report found <italic toggle="yes">Escherichia</italic> to be predominant in patients with aerobic vaginitis [<xref rid="B49-biotech-14-00031" ref-type="bibr">49</xref>,<xref rid="B50-biotech-14-00031" ref-type="bibr">50</xref>]. Particularly, other bacteria identified by LEFSE analysis and associated with healthy women were <italic toggle="yes">Prevotella</italic>, <italic toggle="yes">Limosilactobacillus</italic>, <italic toggle="yes">Streptococcus</italic>, and <italic toggle="yes">Dialister</italic>. The association between Bacterial Vaginosis and increased abundance of anaerobes like <italic toggle="yes">Prevotella</italic>, which is an important source of lipopolysaccharide and ammonia in vaginal mucus, enhances the growth of other bacterial vaginosis-associated organisms like <italic toggle="yes">Gardnerella vaginalis</italic> [<xref rid="B50-biotech-14-00031" ref-type="bibr">50</xref>,<xref rid="B51-biotech-14-00031" ref-type="bibr">51</xref>]. In the case of probiotics, <italic toggle="yes">Limosilactobacillus</italic>, one ex-member of the <italic toggle="yes">Lactobacillus</italic> species, is a probiotic bacterium that can be found in various parts of the human body, like the gastrointestinal tract (GI), urinary tract, skin, and breast milk, and suggests its metabolites promote human health [<xref rid="B51-biotech-14-00031" ref-type="bibr">51</xref>,<xref rid="B52-biotech-14-00031" ref-type="bibr">52</xref>]. In the case of <italic toggle="yes">Streptococcus</italic>, it has been associated with Bacterial Vaginosis in pregnant women, which also presents a dysbiosis of <italic toggle="yes">Lactobacillus</italic> [<xref rid="B53-biotech-14-00031" ref-type="bibr">53</xref>]. The genus <italic toggle="yes">Dialister</italic> also has been associated with higher prevalence and abundance in Bacterial vaginosis [<xref rid="B41-biotech-14-00031" ref-type="bibr">41</xref>].</p></sec><sec sec-type="conclusions" id="sec5-biotech-14-00031"><title>5. Conclusions</title><p>We observed some significant differences in vaginal microbiota composition between women with recurrent vulvovaginal candidiasis (RVVC) and healthy controls. <italic toggle="yes">N. glabratus</italic> (formerly <italic toggle="yes">C. glabrata</italic>) was exclusively detected in RVVC cases, while <italic toggle="yes">C. albicans</italic> was more prevalent in the control group. The vaginal microbiota diversity was relatively low, but we found distinct patterns of bacterial abundance between the two groups. <italic toggle="yes">Bifidobacterium</italic> exhibited an increase in response to RVVC, while antibiotic intake had a mixed effect on bacterial abundance, decreasing it in cases and increasing it in controls. The pathogen <italic toggle="yes">G. vaginalis</italic> (classified as part of <italic toggle="yes">Bifidobacterium</italic>) showed variable responses after antibiotic treatment in both groups of this study. <italic toggle="yes">Lactobacillus</italic> was more prevalent in healthy women when contrasted to RVVC. Other bacteria associated with healthy women included <italic toggle="yes">Prevotella</italic>, <italic toggle="yes">Limosilactobacillus</italic>, <italic toggle="yes">Streptococcus</italic>, and <italic toggle="yes">Dialister</italic>. These observations underscore the importance of further research into the mechanisms behind these associations, with a particular focus on the interactions between <italic toggle="yes">N. glabratus</italic> and vaginal bacteria.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank SECIHTI for Postdoctoral Fellowship Estancias-postdoctorales-por Mexico (321600) granted to CJJ-C, Fellowships granted to JMV-I (959984). Fellowship granted to NdSL-P (1227574), AdlC-M (1311414), and SNI-Ayudante Fellowships granted to DR-S (629184). We are grateful to Rodrigo Garc&#x000ed;a-Guti&#x000e9;rrez for technical support and Viridiana Rosas-Ocegueda for administrative assistance.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-biotech-14-00031"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/biotech14020031/s1">https://www.mdpi.com/article/10.3390/biotech14020031/s1</uri>, Figure S1: Typical Q-Q plot showing normal distribution of age in the studied women; Figure S2: Bar plot showing sequencing depth for each sample, and Figure S3: Bar plot showing sample counts and antibiotic intake in both case and control groups. Table S1: 5&#x02032; to 3&#x02032; sequence of barcoded primers for bacteria used in this study; Table S2: Diagnostic primers for yeast detection, and Table S3: Sequencing summary.</p><supplementary-material id="biotech-14-00031-s001" position="float" content-type="local-data"><media xlink:href="biotech-14-00031-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, C.M.-B. and J.G.-M.; methodology, J.P.-D., C.M.-B., C.J.J.-C., A.P.-E., N.d.S.L.-P., A.d.l.C.-M., D.R.-S., Y.G.-M., J.M.V.-I. and J.G.-M.; software, J.M.V.-I.; validation, C.J.J.-C.; formal analysis, J.M.V.-I.; investigation, J.P.-D., C.M.-B., C.J.J.-C., A.P.-E., N.d.S.L.-P., A.d.l.C.-M., D.R.-S., Y.G.-M., J.M.V.-I. and J.G.-M.; resources, Y.G.-M. and J.G.-M.; data curation, C.M.-B., C.J.J.-C. and J.G.-M.; writing&#x02014;original draft preparation, C.M.-B., C.J.J.-C., D.R.-S., J.M.V.-I. and J.G.-M.; writing&#x02014;review and editing, J.P-D., C.M.-B., C.J.J.-C., A.P.-E., N.d.S.L.-P., A.d.l.C.-M., D.R.-S., Y.G.-M., J.M.V.-I. and J.G.-M.; visualization, J.G.-M. and J.M.V.-I.; supervision, J.G.-M., A.P.-E. and C.J.J.-C.; project administration, C.M.-B. and J.G.-M.; funding acquisition, J.G.-M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Committee of Research and the Ethics in Research Committee of the ABC Medical Center (Project identification code: 2016-06-23).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets generated for this study can be found in the NCBI BioProject ID PRJNA1199545 Link <uri xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1199545">https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1199545</uri> (accessed on 10 April 2025).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-biotech-14-00031"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moosa</surname><given-names>Y.</given-names></name>
<name><surname>Kwon</surname><given-names>D.</given-names></name>
<name><surname>de Oliveira</surname><given-names>T.</given-names></name>
<name><surname>Wong</surname><given-names>E.B.</given-names></name>
</person-group><article-title>Determinants of Vaginal Microbiota Composition</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>467</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00467</pub-id><pub-id pub-id-type="pmid">32984081</pub-id>
</element-citation></ref><ref id="B2-biotech-14-00031"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chee</surname><given-names>W.J.Y.</given-names></name>
<name><surname>Chew</surname><given-names>S.Y.</given-names></name>
<name><surname>Than</surname><given-names>L.T.L.</given-names></name>
</person-group><article-title>Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health</article-title><source>Microb. Cell Factories</source><year>2020</year><volume>19</volume><fpage>203</fpage><pub-id pub-id-type="doi">10.1186/s12934-020-01464-4</pub-id></element-citation></ref><ref id="B3-biotech-14-00031"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
</person-group><article-title>Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e27239</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e27239</pub-id><pub-id pub-id-type="pmid">38463778</pub-id>
</element-citation></ref><ref id="B4-biotech-14-00031"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Ge</surname><given-names>X.</given-names></name>
<name><surname>Qiu</surname><given-names>B.</given-names></name>
<name><surname>Xiang</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2023</year><volume>13</volume><elocation-id>1123026</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1123026</pub-id><pub-id pub-id-type="pmid">36816582</pub-id>
</element-citation></ref><ref id="B5-biotech-14-00031"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalia</surname><given-names>N.</given-names></name>
<name><surname>Singh</surname><given-names>J.</given-names></name>
<name><surname>Kaur</surname><given-names>M.</given-names></name>
</person-group><article-title>Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: A critical review</article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><year>2020</year><volume>19</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/s12941-020-0347-4</pub-id><pub-id pub-id-type="pmid">31992328</pub-id>
</element-citation></ref><ref id="B6-biotech-14-00031"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Williams</surname><given-names>C.J.</given-names></name>
<name><surname>Hochwalt</surname><given-names>A.</given-names></name>
<name><surname>Forney</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Bacterial Populations in the Vaginas of Healthy Adolescent Women</article-title><source>J. Pediatr. Adolesc. Gynecol.</source><year>2009</year><volume>22</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.jpag.2008.01.073</pub-id><pub-id pub-id-type="pmid">19232297</pub-id>
</element-citation></ref><ref id="B7-biotech-14-00031"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-S&#x000e1;nchez</surname><given-names>A.</given-names></name>
<name><surname>Reyes-Lagos</surname><given-names>J.J.</given-names></name>
<name><surname>Pe&#x000f1;a-Castillo</surname><given-names>M.A.</given-names></name>
<name><surname>Nirmalkar</surname><given-names>K.</given-names></name>
<name><surname>Garc&#x000ed;a-Mena</surname><given-names>J.</given-names></name>
<name><surname>Pacheco-L&#x000f3;pez</surname><given-names>G.</given-names></name>
</person-group><article-title>Vaginal Microbiota Is Stable and Mainly Dominated by Lactobacillus at Third Trimester of Pregnancy and Active Childbirth: A Longitudinal Study of Ten Mexican Women</article-title><source>Curr. Microbiol.</source><year>2022</year><volume>79</volume><elocation-id>230</elocation-id><pub-id pub-id-type="doi">10.1007/s00284-022-02918-1</pub-id><pub-id pub-id-type="pmid">35767085</pub-id>
</element-citation></ref><ref id="B8-biotech-14-00031"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hern&#x000e1;ndez-Rodr&#x000ed;guez</surname><given-names>C.</given-names></name>
<name><surname>Romero-Gonz&#x000e1;lez</surname><given-names>R.</given-names></name>
<name><surname>Albani-Campanario</surname><given-names>M.</given-names></name>
<name><surname>Figueroa-Dami&#x000e1;n</surname><given-names>R.</given-names></name>
<name><surname>Meraz-Cruz</surname><given-names>N.</given-names></name>
<name><surname>Hern&#x000e1;ndez-Guerrero</surname><given-names>C.</given-names></name>
</person-group><article-title>Vaginal Microbiota of Healthy Pregnant Mexican Women is Constituted by Four Lactobacillus Species and Several Vaginosis-Associated Bacteria</article-title><source>Infect. Dis. Obstet. Gynecol.</source><year>2011</year><volume>2011</volume><fpage>851485</fpage><pub-id pub-id-type="doi">10.1155/2011/851485</pub-id><pub-id pub-id-type="pmid">21960733</pub-id>
</element-citation></ref><ref id="B9-biotech-14-00031"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willems</surname><given-names>H.M.E.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.S.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Peters</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Vulvovaginal Candidiasis: A Current Understanding and Burning Questions</article-title><source>J. Fungi</source><year>2020</year><volume>6</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.3390/jof6010027</pub-id></element-citation></ref><ref id="B10-biotech-14-00031"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anahtar</surname><given-names>M.N.</given-names></name>
<name><surname>Gootenberg</surname><given-names>D.B.</given-names></name>
<name><surname>Mitchell</surname><given-names>C.M.</given-names></name>
<name><surname>Kwon</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Cervicovaginal Microbiota and Reproductive Health: The Virtue of Simplicity</article-title><source>Cell Host Microbe</source><year>2018</year><volume>23</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.01.013</pub-id><pub-id pub-id-type="pmid">29447695</pub-id>
</element-citation></ref><ref id="B11-biotech-14-00031"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Younes</surname><given-names>J.A.</given-names></name>
<name><surname>Lievens</surname><given-names>E.</given-names></name>
<name><surname>Hummelen</surname><given-names>R.</given-names></name>
<name><surname>van der Westen</surname><given-names>R.</given-names></name>
<name><surname>Reid</surname><given-names>G.</given-names></name>
<name><surname>Petrova</surname><given-names>M.I.</given-names></name>
</person-group><article-title>Women and Their Microbes: The Unexpected Friendship</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>16</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2017.07.008</pub-id><pub-id pub-id-type="pmid">28844447</pub-id>
</element-citation></ref><ref id="B12-biotech-14-00031"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Granada</surname><given-names>M.</given-names></name>
<name><surname>Cook</surname><given-names>E.</given-names></name>
<name><surname>Sherlock</surname><given-names>G.</given-names></name>
<name><surname>Rosenzweig</surname><given-names>F.</given-names></name>
</person-group><article-title>Microbe Profile: Candida glabrata&#x02014;A master of deception: This article is part of the Microbe Profiles collection</article-title><source>Microbiology</source><year>2024</year><volume>170</volume><elocation-id>001518</elocation-id><pub-id pub-id-type="doi">10.1099/mic.0.001518</pub-id><pub-id pub-id-type="pmid">39589236</pub-id>
</element-citation></ref><ref id="B13-biotech-14-00031"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takashima</surname><given-names>M.</given-names></name>
<name><surname>Sugita</surname><given-names>T.</given-names></name>
</person-group><article-title>Taxonomy of Pathogenic Yeasts <italic toggle="yes">Candida</italic>, <italic toggle="yes">Cryptococcus</italic>, <italic toggle="yes">Malassezia</italic>, and <italic toggle="yes">Trichosporon</italic>: Current Status, Future Perspectives, and Proposal for Transfer of Six <italic toggle="yes">Candida</italic> Species to the Genus <italic toggle="yes">Nakaseomyces</italic></article-title><source>Med. Mycol. J.</source><year>2022</year><volume>63</volume><fpage>119</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.3314/mmj.22.004</pub-id><pub-id pub-id-type="pmid">36450564</pub-id>
</element-citation></ref><ref id="B14-biotech-14-00031"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hern&#x000e1;ndez-Quiroz</surname><given-names>F.</given-names></name>
<name><surname>Murugesan</surname><given-names>S.</given-names></name>
<name><surname>Flores-Rivas</surname><given-names>C.</given-names></name>
<name><surname>Pi&#x000f1;a-Escobedo</surname><given-names>A.</given-names></name>
<name><surname>Ju&#x000e1;rez-Hern&#x000e1;ndez</surname><given-names>J.I.</given-names></name>
<name><surname>Garc&#x000ed;a-Espitia</surname><given-names>M.</given-names></name>
<name><surname>Ch&#x000e1;vez-Carbajal</surname><given-names>A.</given-names></name>
<name><surname>Nirmalkar</surname><given-names>K.</given-names></name>
<name><surname>Garc&#x000ed;a-Mena</surname><given-names>J.</given-names></name>
</person-group><article-title>A high-throughput DNA sequencing study of fecal bacteria of seven Mexican horse breeds</article-title><source>Arch. Microbiol.</source><year>2022</year><volume>204</volume><elocation-id>382</elocation-id><pub-id pub-id-type="doi">10.1007/s00203-022-03009-2</pub-id><pub-id pub-id-type="pmid">35687150</pub-id>
</element-citation></ref><ref id="B15-biotech-14-00031"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>G.</given-names></name>
<name><surname>Mitchell</surname><given-names>T.G.</given-names></name>
</person-group><article-title>Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR</article-title><source>J. Clin. Microbiol.</source><year>2002</year><volume>40</volume><fpage>2860</fpage><lpage>2865</lpage><pub-id pub-id-type="doi">10.1128/JCM.40.8.2860-2865.2002</pub-id><pub-id pub-id-type="pmid">12149343</pub-id>
</element-citation></ref><ref id="B16-biotech-14-00031"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muir</surname><given-names>A.</given-names></name>
<name><surname>Harrison</surname><given-names>E.</given-names></name>
<name><surname>Wheals</surname><given-names>A.</given-names></name>
</person-group><article-title>A multiplex set of species-specific primers for rapid identification of members of the genus Saccharomyces</article-title><source>FEMS Yeast Res.</source><year>2011</year><volume>11</volume><fpage>552</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1111/j.1567-1364.2011.00745.x</pub-id><pub-id pub-id-type="pmid">22093682</pub-id>
</element-citation></ref><ref id="B17-biotech-14-00031"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolyen</surname><given-names>E.</given-names></name>
<name><surname>Rideout</surname><given-names>J.R.</given-names></name>
<name><surname>Dillon</surname><given-names>M.R.</given-names></name>
<name><surname>Bokulich</surname><given-names>N.A.</given-names></name>
<name><surname>Abnet</surname><given-names>C.C.</given-names></name>
<name><surname>Al-Ghalith</surname><given-names>G.A.</given-names></name>
<name><surname>Alexander</surname><given-names>H.</given-names></name>
<name><surname>Alm</surname><given-names>E.J.</given-names></name>
<name><surname>Arumugam</surname><given-names>M.</given-names></name>
<name><surname>Asnicar</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2</article-title><source>Nat. Biotechnol.</source><year>2019</year><volume>37</volume><fpage>852</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0209-9</pub-id><pub-id pub-id-type="pmid">31341288</pub-id>
</element-citation></ref><ref id="B18-biotech-14-00031"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>D.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Balaban</surname><given-names>M.</given-names></name>
<name><surname>Cantrell</surname><given-names>K.</given-names></name>
<name><surname>Zhu</surname><given-names>Q.</given-names></name>
<name><surname>Gonzalez</surname><given-names>A.</given-names></name>
<name><surname>Morton</surname><given-names>J.T.</given-names></name>
<name><surname>Nicolaou</surname><given-names>G.</given-names></name>
<name><surname>Parks</surname><given-names>D.H.</given-names></name>
<name><surname>Karst</surname><given-names>S.M.</given-names></name>
<etal/>
</person-group><article-title>Greengenes2 unifies microbial data in a single reference tree</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>42</volume><fpage>715</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01845-1</pub-id><pub-id pub-id-type="pmid">37500913</pub-id>
</element-citation></ref><ref id="B19-biotech-14-00031"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>R Core Team</collab>
</person-group><source>R: A Language and Environment for Statistical Computing</source><publisher-name>R Foundation for Statistical Computing</publisher-name><publisher-loc>Vienna, Austria</publisher-loc><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-17">(accessed on 17 November 2024)</date-in-citation></element-citation></ref><ref id="B20-biotech-14-00031"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Posit Team</collab>
</person-group><source>RStudio: Integrated Development Environment for R</source><publisher-name>Posit Software, PBC</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2023</year><comment>Available online: <ext-link xlink:href="http://www.posit.co/" ext-link-type="uri">http://www.posit.co/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-17">(accessed on 17 October 2024)</date-in-citation></element-citation></ref><ref id="B21-biotech-14-00031"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McMurdie</surname><given-names>P.J.</given-names></name>
<name><surname>Holmes</surname><given-names>S.</given-names></name>
</person-group><article-title>phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e61217</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0061217</pub-id><pub-id pub-id-type="pmid">23630581</pub-id>
</element-citation></ref><ref id="B22-biotech-14-00031"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Love</surname><given-names>M.I.</given-names></name>
<name><surname>Huber</surname><given-names>W.</given-names></name>
<name><surname>Anders</surname><given-names>S.</given-names></name>
</person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation></ref><ref id="B23-biotech-14-00031"><label>23.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Bisanz</surname><given-names>J.E.</given-names></name>
</person-group><article-title>qiime2R: Importing QIIME2 Artifacts and Associated Data into R Sessions</article-title><year>2018</year><comment>Available online: <ext-link xlink:href="https://github.com/jbisanz/qiime2R" ext-link-type="uri">https://github.com/jbisanz/qiime2R</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-17">(accessed on 17 October 2024)</date-in-citation></element-citation></ref><ref id="B24-biotech-14-00031"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nixon</surname><given-names>M.P.</given-names></name>
<name><surname>McGovern</surname><given-names>K.C.</given-names></name>
<name><surname>Letourneau</surname><given-names>J.</given-names></name>
<name><surname>David</surname><given-names>L.A.</given-names></name>
<name><surname>Lazar</surname><given-names>N.A.</given-names></name>
<name><surname>Mukherjee</surname><given-names>S.</given-names></name>
<name><surname>Silverman</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Scale Reliant Inference</article-title><source>arXiv</source><year>2024</year><pub-id pub-id-type="doi">10.48550/arXiv.2201.03616</pub-id><pub-id pub-id-type="arxiv">2201.03616</pub-id></element-citation></ref><ref id="B25-biotech-14-00031"><label>25.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Oksanen</surname><given-names>J.</given-names></name>
<name><surname>Blanchet</surname><given-names>F.G.</given-names></name>
<name><surname>Friendly</surname><given-names>M.</given-names></name>
<name><surname>Kindt</surname><given-names>R.</given-names></name>
<name><surname>Legendre</surname><given-names>P.</given-names></name>
<name><surname>McGlinn</surname><given-names>D.</given-names></name>
<name><surname>Minchin</surname><given-names>P.R.</given-names></name>
<name><surname>O&#x02019;Hara</surname><given-names>R.B.</given-names></name>
<name><surname>Simpson</surname><given-names>G.L.</given-names></name>
<name><surname>Solymos</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>vegan: Community Ecology Package. 28 de Agosto de 2024</article-title><comment>Available online: <ext-link xlink:href="https://cran.r-project.org/web/packages/vegan/index.html" ext-link-type="uri">https://cran.r-project.org/web/packages/vegan/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-17">(accessed on 17 December 2024)</date-in-citation></element-citation></ref><ref id="B26-biotech-14-00031"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khleborodova</surname><given-names>A.</given-names></name>
<name><surname>Gamboa-Tuz</surname><given-names>S.D.</given-names></name>
<name><surname>Ramos</surname><given-names>M.</given-names></name>
<name><surname>Segata</surname><given-names>N.</given-names></name>
<name><surname>Waldron</surname><given-names>L.</given-names></name>
<name><surname>Oh</surname><given-names>S.</given-names></name>
</person-group><article-title>Lefser: Implementation of metagenomic biomarker discovery tool, LEfSe, in R</article-title><source>Bioinformatics</source><year>2024</year><volume>40</volume><elocation-id>btae707</elocation-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btae707</pub-id><pub-id pub-id-type="pmid">39585730</pub-id>
</element-citation></ref><ref id="B27-biotech-14-00031"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Complex heatmap visualization</article-title><source>iMeta</source><year>2022</year><volume>1</volume><fpage>e43</fpage><pub-id pub-id-type="doi">10.1002/imt2.43</pub-id><pub-id pub-id-type="pmid">38868715</pub-id>
</element-citation></ref><ref id="B28-biotech-14-00031"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wickham</surname><given-names>H.</given-names></name>
<name><surname>Averick</surname><given-names>M.</given-names></name>
<name><surname>Bryan</surname><given-names>J.</given-names></name>
<name><surname>Chang</surname><given-names>W.</given-names></name>
<name><surname>McGowan</surname><given-names>L.D.A.</given-names></name>
<name><surname>Fran&#x000e7;ois</surname><given-names>R.</given-names></name>
<name><surname>Grolemund</surname><given-names>G.</given-names></name>
<name><surname>Hayes</surname><given-names>A.</given-names></name>
<name><surname>Henry</surname><given-names>L.</given-names></name>
<name><surname>Hester</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Welcome to the Tidyverse</article-title><source>J. Open Source Softw.</source><year>2019</year><volume>4</volume><fpage>1686</fpage><pub-id pub-id-type="doi">10.21105/joss.01686</pub-id></element-citation></ref><ref id="B29-biotech-14-00031"><label>29.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Auguie</surname><given-names>B.</given-names></name>
<name><surname>Antonov</surname><given-names>A.</given-names></name>
</person-group><article-title>gridExtra: Miscellaneous Functions for &#x000ab;Grid&#x000bb; Graphics. 9 de Septiembre de 2017</article-title><comment>Available online: <ext-link xlink:href="https://cran.r-project.org/web/packages/gridExtra/" ext-link-type="uri">https://cran.r-project.org/web/packages/gridExtra/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-17">(accessed on 17 December 2024)</date-in-citation></element-citation></ref><ref id="B30-biotech-14-00031"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sobel</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Vulvovaginal candidosis</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>1961</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60917-9</pub-id><pub-id pub-id-type="pmid">17560449</pub-id>
</element-citation></ref><ref id="B31-biotech-14-00031"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blostein</surname><given-names>F.</given-names></name>
<name><surname>Levin-Sparenberg</surname><given-names>E.</given-names></name>
<name><surname>Wagner</surname><given-names>J.</given-names></name>
<name><surname>Foxman</surname><given-names>B.</given-names></name>
</person-group><article-title>Recurrent vulvovaginal candidiasis</article-title><source>Ann. Epidemiol.</source><year>2017</year><volume>27</volume><fpage>575</fpage><lpage>582.e3</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2017.08.010</pub-id><pub-id pub-id-type="pmid">28927765</pub-id>
</element-citation></ref><ref id="B32-biotech-14-00031"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yano</surname><given-names>J.</given-names></name>
<name><surname>Sobel</surname><given-names>J.D.</given-names></name>
<name><surname>Nyirjesy</surname><given-names>P.</given-names></name>
<name><surname>Sobel</surname><given-names>R.</given-names></name>
<name><surname>Williams</surname><given-names>V.L.</given-names></name>
<name><surname>Yu</surname><given-names>Q.</given-names></name>
<name><surname>Noverr</surname><given-names>M.C.</given-names></name>
<name><surname>Fidel</surname><given-names>P.L.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Current patient perspectives of vulvovaginal candidiasis: Incidence, symptoms, management and post-treatment outcomes</article-title><source>BMC Women&#x02019;s Health</source><year>2019</year><volume>19</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/s12905-019-0748-8</pub-id><pub-id pub-id-type="pmid">30925872</pub-id>
</element-citation></ref><ref id="B33-biotech-14-00031"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>S.</given-names></name>
<name><surname>Negri</surname><given-names>M.</given-names></name>
<name><surname>Henriques</surname><given-names>M.</given-names></name>
<name><surname>Oliveira</surname><given-names>R.</given-names></name>
<name><surname>Williams</surname><given-names>D.W.</given-names></name>
<name><surname>Azeredo</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">Candida glabrata</italic>, <italic toggle="yes">Candida parapsilosis</italic> and <italic toggle="yes">Candida tropicalis</italic>: Biology, epidemiology, pathogenicity and antifungal resistance</article-title><source>FEMS Microbiol. Rev.</source><year>2012</year><volume>36</volume><fpage>288</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2011.00278.x</pub-id><pub-id pub-id-type="pmid">21569057</pub-id>
</element-citation></ref><ref id="B34-biotech-14-00031"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chow</surname><given-names>A.W.</given-names></name>
<name><surname>Percival-Smith</surname><given-names>R.</given-names></name>
<name><surname>Bartlett</surname><given-names>K.H.</given-names></name>
<name><surname>Goldring</surname><given-names>A.M.</given-names></name>
<name><surname>Morrison</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Vaginal colonization with Escherichia coli in healthy women: Determination of relative risks by quantitative culture and multivariate statistical analysis</article-title><source>Am. J. Obstet. Gynecol.</source><year>1986</year><volume>154</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/0002-9378(86)90406-0</pub-id><pub-id pub-id-type="pmid">3511702</pub-id>
</element-citation></ref><ref id="B35-biotech-14-00031"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldacre</surname><given-names>M.J.</given-names></name>
<name><surname>Watt</surname><given-names>B.</given-names></name>
<name><surname>Loudon</surname><given-names>N.</given-names></name>
<name><surname>Milne</surname><given-names>L.J.</given-names></name>
<name><surname>Loudon</surname><given-names>J.D.</given-names></name>
<name><surname>Vessey</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Vaginal microbial flora in normal young women</article-title><source>BMJ</source><year>1979</year><volume>1</volume><fpage>1450</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1136/bmj.1.6176.1450</pub-id><pub-id pub-id-type="pmid">380743</pub-id>
</element-citation></ref><ref id="B36-biotech-14-00031"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gow</surname><given-names>N.A.</given-names></name>
<name><surname>Hube</surname><given-names>B.</given-names></name>
</person-group><article-title>Importance of the <italic toggle="yes">Candida albicans</italic> cell wall during commensalism and infection</article-title><source>Curr. Opin. Microbiol.</source><year>2012</year><volume>15</volume><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2012.04.005</pub-id><pub-id pub-id-type="pmid">22609181</pub-id>
</element-citation></ref><ref id="B37-biotech-14-00031"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubourg</surname><given-names>G.</given-names></name>
<name><surname>Lagier</surname><given-names>J.C.</given-names></name>
<name><surname>Robert</surname><given-names>C.</given-names></name>
<name><surname>Armougom</surname><given-names>F.</given-names></name>
<name><surname>Hugon</surname><given-names>P.</given-names></name>
<name><surname>Metidji</surname><given-names>S.</given-names></name>
<name><surname>Dione</surname><given-names>N.</given-names></name>
<name><surname>Dangui</surname><given-names>N.P.M.</given-names></name>
<name><surname>Pfleiderer</surname><given-names>A.</given-names></name>
<name><surname>Abrahao</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Culturomics and pyrosequencing evidence of the reduction in gut microbiota diversity in patients with broad-spectrum antibiotics</article-title><source>Int. J. Antimicrob. Agents</source><year>2014</year><volume>44</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.04.020</pub-id><pub-id pub-id-type="pmid">25063078</pub-id>
</element-citation></ref><ref id="B38-biotech-14-00031"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lev-Sagie</surname><given-names>A.</given-names></name>
<name><surname>Goldman-Wohl</surname><given-names>D.</given-names></name>
<name><surname>Cohen</surname><given-names>Y.</given-names></name>
<name><surname>Dori-Bachash</surname><given-names>M.</given-names></name>
<name><surname>Leshem</surname><given-names>A.</given-names></name>
<name><surname>Mor</surname><given-names>U.</given-names></name>
<name><surname>Strahilevitz</surname><given-names>J.</given-names></name>
<name><surname>Moses</surname><given-names>A.E.</given-names></name>
<name><surname>Shapiro</surname><given-names>H.</given-names></name>
<name><surname>Yagel</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Vaginal microbiome transplantation in women with intractable bacterial vaginosis</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>1500</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0600-6</pub-id><pub-id pub-id-type="pmid">31591599</pub-id>
</element-citation></ref><ref id="B39-biotech-14-00031"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theriot</surname><given-names>C.M.</given-names></name>
<name><surname>Koenigsknecht</surname><given-names>M.J.</given-names></name>
<name><surname>Carlson</surname><given-names>P.E.</given-names><suffix>Jr.</suffix></name>
<name><surname>Hatton</surname><given-names>G.E.</given-names></name>
<name><surname>Nelson</surname><given-names>A.M.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Huffnagle</surname><given-names>G.B.</given-names></name>
<name><surname>Li</surname><given-names>J.Z.</given-names></name>
<name><surname>Young</surname><given-names>V.B.</given-names></name>
</person-group><article-title>Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3114</fpage><pub-id pub-id-type="doi">10.1038/ncomms4114</pub-id><pub-id pub-id-type="pmid">24445449</pub-id>
</element-citation></ref><ref id="B40-biotech-14-00031"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceccarani</surname><given-names>C.</given-names></name>
<name><surname>Foschi</surname><given-names>C.</given-names></name>
<name><surname>Parolin</surname><given-names>C.</given-names></name>
<name><surname>D&#x02019;antuono</surname><given-names>A.</given-names></name>
<name><surname>Gaspari</surname><given-names>V.</given-names></name>
<name><surname>Consolandi</surname><given-names>C.</given-names></name>
<name><surname>Laghi</surname><given-names>L.</given-names></name>
<name><surname>Camboni</surname><given-names>T.</given-names></name>
<name><surname>Vitali</surname><given-names>B.</given-names></name>
<name><surname>Severgnini</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Diversity of vaginal microbiome and metabolome during genital infections</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>14095</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-50410-x</pub-id><pub-id pub-id-type="pmid">31575935</pub-id>
</element-citation></ref><ref id="B41-biotech-14-00031"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C.M.</given-names></name>
<name><surname>Hungate</surname><given-names>B.A.</given-names></name>
<name><surname>Tobian</surname><given-names>A.A.R.</given-names></name>
<name><surname>Ravel</surname><given-names>J.</given-names></name>
<name><surname>Prodger</surname><given-names>J.L.</given-names></name>
<name><surname>Serwadda</surname><given-names>D.</given-names></name>
<name><surname>Kigozi</surname><given-names>G.</given-names></name>
<name><surname>Galiwango</surname><given-names>R.M.</given-names></name>
<name><surname>Nalugoda</surname><given-names>F.</given-names></name>
<name><surname>Keim</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Penile Microbiota and Female Partner Bacterial Vaginosis in Rakai, Uganda</article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e00589-15</fpage><pub-id pub-id-type="doi">10.1128/mBio.00589-15</pub-id><pub-id pub-id-type="pmid">26081632</pub-id>
</element-citation></ref><ref id="B42-biotech-14-00031"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chopyk</surname><given-names>J.</given-names></name>
<name><surname>G&#x000fc;emes</surname><given-names>A.G.C.</given-names></name>
<name><surname>Ramirez-Sanchez</surname><given-names>C.</given-names></name>
<name><surname>Attai</surname><given-names>H.</given-names></name>
<name><surname>Ly</surname><given-names>M.</given-names></name>
<name><surname>Jones</surname><given-names>M.B.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
<name><surname>Tu</surname><given-names>X.M.</given-names></name>
<etal/>
</person-group><article-title>Common antibiotics, azithromycin and amoxicillin, affect gut metagenomics within a household</article-title><source>BMC Microbiol.</source><year>2023</year><volume>23</volume><elocation-id>206</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-023-02949-z</pub-id><pub-id pub-id-type="pmid">37528343</pub-id>
</element-citation></ref><ref id="B43-biotech-14-00031"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bagnall</surname><given-names>P.</given-names></name>
<name><surname>Rizzolo</surname><given-names>D.</given-names></name>
</person-group><article-title>Bacterial vaginosis: A practical review</article-title><source>J. Am. Acad. Physician Assist.</source><year>2017</year><volume>30</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1097/01.JAA.0000526770.60197.fa</pub-id></element-citation></ref><ref id="B44-biotech-14-00031"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morrill</surname><given-names>S.</given-names></name>
<name><surname>Gilbert</surname><given-names>N.M.</given-names></name>
<name><surname>Lewis</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Gardnerella vaginalis as a Cause of Bacterial Vaginosis: Appraisal of the Evidence From in vivo Models</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00168</pub-id><pub-id pub-id-type="pmid">32391287</pub-id>
</element-citation></ref><ref id="B45-biotech-14-00031"><label>45.</label><element-citation publication-type="webpage"><article-title>Reclassification of the Bifidobacterium and Gardnerella Genera</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.atcc.org/resources/posters/2019-posters/reclassification-of-the-bifidobacterium-and-gardnerella-genera" ext-link-type="uri">https://www.atcc.org/resources/posters/2019-posters/reclassification-of-the-bifidobacterium-and-gardnerella-genera</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-17">(accessed on 17 December 2024)</date-in-citation></element-citation></ref><ref id="B46-biotech-14-00031"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahrens</surname><given-names>P.</given-names></name>
<name><surname>Andersen</surname><given-names>L.O.</given-names></name>
<name><surname>Lilje</surname><given-names>B.</given-names></name>
<name><surname>Johannesen</surname><given-names>T.B.</given-names></name>
<name><surname>Dahl</surname><given-names>E.G.</given-names></name>
<name><surname>Baig</surname><given-names>S.</given-names></name>
<name><surname>Jensen</surname><given-names>J.S.</given-names></name>
<name><surname>Falk</surname><given-names>L.</given-names></name>
</person-group><article-title>Changes in the vaginal microbiota following antibiotic treatment for Mycoplasma genitalium, Chlamydia trachomatis and bacterial vaginosis</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0236036</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0236036</pub-id><pub-id pub-id-type="pmid">32722712</pub-id>
</element-citation></ref><ref id="B47-biotech-14-00031"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zwittink</surname><given-names>R.D.</given-names></name>
<name><surname>Munckhof</surname><given-names>E.H.A.v.D.</given-names></name>
<name><surname>Hall</surname><given-names>M.A.L.-V.</given-names></name>
<name><surname>Boers</surname><given-names>K.</given-names></name>
<name><surname>Molijn</surname><given-names>A.</given-names></name>
<name><surname>Knetsch</surname><given-names>C.W.</given-names></name>
<name><surname>Kuijper</surname><given-names>E.J.</given-names></name>
</person-group><article-title>The vaginal microbiota in the course of bacterial vaginosis treatment</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2021</year><volume>40</volume><fpage>651</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1007/s10096-020-04049-6</pub-id><pub-id pub-id-type="pmid">33029765</pub-id>
</element-citation></ref><ref id="B48-biotech-14-00031"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theis</surname><given-names>K.R.</given-names></name>
<name><surname>Florova</surname><given-names>V.</given-names></name>
<name><surname>Romero</surname><given-names>R.</given-names></name>
<name><surname>Borisov</surname><given-names>A.B.</given-names></name>
<name><surname>Winters</surname><given-names>A.D.</given-names></name>
<name><surname>Galaz</surname><given-names>J.</given-names></name>
<name><surname>Gomez-Lopez</surname><given-names>N.</given-names></name>
</person-group><article-title>Sneathia: An emerging pathogen in female reproductive disease and adverse perinatal outcomes</article-title><source>Crit. Rev. Microbiol.</source><year>2021</year><volume>47</volume><fpage>517</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1080/1040841X.2021.1905606</pub-id><pub-id pub-id-type="pmid">33823747</pub-id>
</element-citation></ref><ref id="B49-biotech-14-00031"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pramanick</surname><given-names>R.</given-names></name>
<name><surname>Nathani</surname><given-names>N.</given-names></name>
<name><surname>Warke</surname><given-names>H.</given-names></name>
<name><surname>Mayadeo</surname><given-names>N.</given-names></name>
<name><surname>Aranha</surname><given-names>C.</given-names></name>
</person-group><article-title>Vaginal Dysbiotic Microbiome in Women with No Symptoms of Genital Infections</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>11</volume><elocation-id>760459</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.760459</pub-id><pub-id pub-id-type="pmid">35096634</pub-id>
</element-citation></ref><ref id="B50-biotech-14-00031"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>D.</given-names></name>
<name><surname>Parween</surname><given-names>S.</given-names></name>
<name><surname>Kumari</surname><given-names>K.</given-names></name>
<name><surname>Singh</surname><given-names>N.</given-names></name>
</person-group><article-title>Prevalence, Etiology, and Associated Symptoms of Vaginal Discharge During Pregnancy in Women Seen in a Tertiary Care Hospital in Bihar</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e12700</fpage><pub-id pub-id-type="doi">10.7759/cureus.12700</pub-id><pub-id pub-id-type="pmid">33614308</pub-id>
</element-citation></ref><ref id="B51-biotech-14-00031"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Randis</surname><given-names>T.M.</given-names></name>
<name><surname>Ratner</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Gardnerella and Prevotella: Co-conspirators in the Pathogenesis of Bacterial Vaginosis</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>220</volume><fpage>1085</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy705</pub-id><pub-id pub-id-type="pmid">30715397</pub-id>
</element-citation></ref><ref id="B52-biotech-14-00031"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abuqwider</surname><given-names>J.</given-names></name>
<name><surname>Altamimi</surname><given-names>M.</given-names></name>
<name><surname>Mauriello</surname><given-names>G.</given-names></name>
</person-group><article-title>Limosilactobacillus reuteri in Health and Disease</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><elocation-id>522</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms10030522</pub-id><pub-id pub-id-type="pmid">35336098</pub-id>
</element-citation></ref><ref id="B53-biotech-14-00031"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>I.</given-names></name>
<name><surname>Zakeer</surname><given-names>S.</given-names></name>
<name><surname>Azab</surname><given-names>M.</given-names></name>
<name><surname>Hanora</surname><given-names>A.</given-names></name>
</person-group><article-title>Changes in Vaginal Microbiome in Pregnant and Nonpregnant Women with Bacterial Vaginosis: Toward Microbiome Diagnostics?</article-title><source>OMICS J. Integr. Biol.</source><year>2020</year><volume>24</volume><fpage>602</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1089/omi.2020.0096</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="biotech-14-00031-f001"><label>Figure 1</label><caption><p>Main variables driving the study. (<bold>A</bold>). Histogram depicting the age (in years) distribution between control and case groups. No statistical difference was found according to the Student&#x02019;s <italic toggle="yes">t</italic>-test. (<bold>B</bold>). Barplot showing antibiotic intake in women. (<bold>C</bold>). Barplot showing the proportion of control and case groups with three different fungi detected by PCR.</p></caption><graphic xlink:href="biotech-14-00031-g001" position="float"/></fig><fig position="float" id="biotech-14-00031-f002"><label>Figure 2</label><caption><p>Diversity metrics for stratified groups, considering antibiotic intake and condition (case vs. control). (<bold>A</bold>). Violin plot depicting alpha diversity metrics (Observed number of ASVs, Shannon, Simpson, and Fisher) for the groups. (<bold>B</bold>). Scatter plot showing Non-Metric Multidimensional Scaling (NMDS) for weighted Unifrac distance for beta diversity assessment in the groups. ADONIS was applied to account for the variance explained by Condition (<italic toggle="yes">p</italic> = 0.036, <inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> = 0.05) and Antibiotic intake (<italic toggle="yes">p</italic> = 0.39, <inline-formula><mml:math id="mm4" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> = 0.01). (<bold>C</bold>). Scatter plot showing Non-Metric Multidimensional Scaling (NMDS) for unweighted Unifrac distance for beta diversity assessment in the groups. ADONIS was applied to account for the variance explained by Condition (<italic toggle="yes">p</italic> = 0.012, <inline-formula><mml:math id="mm5" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> = 0.03) and Antibiotic intake (<italic toggle="yes">p</italic> = 0.018, <inline-formula><mml:math id="mm6" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> = 0.03).</p></caption><graphic xlink:href="biotech-14-00031-g002" position="float"/></fig><fig position="float" id="biotech-14-00031-f003"><label>Figure 3</label><caption><p>Relative abundance for stratified groups, considering antibiotic intake and condition (case vs. control). (<bold>A</bold>). Phylum relative abundance as percentages. (<bold>B</bold>). Genus relative abundance as percentages. Taxa are identified on the right side of each figure.</p></caption><graphic xlink:href="biotech-14-00031-g003" position="float"/></fig><fig position="float" id="biotech-14-00031-f004"><label>Figure 4</label><caption><p>Important biomarker bacteria considering antibiotic intake and condition. (<bold>A</bold>,<bold>B</bold>), Using ALDEx2 (&#x0201c;<inline-formula><mml:math id="mm7" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mo>&#x0223c;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> antibiotic intake + RVVC condition&#x0201d;). (<bold>C</bold>,<bold>D</bold>), using LEFSE (Class = RVVC, Subclass = antibiotic intake). Only features with p-values that passed FDR correction were included in the graphs. (<bold>A</bold>). Barplot showing ALDEx2 results for condition (case vs. control). The X-axis shows the effect, and the Y-axis shows the genus. Negative values correspond to control, positive values correspond to cases. (<bold>B</bold>). Barplot of mean sqrt of relative abundance of taxa found by ALDEx2. The X-axis shows the mean sqrt of relative abundance, and the Y-axis shows the genera. (<bold>C</bold>). Barplot showing LEFSE results for condition (case vs. control). The X-axis shows the LDA scores, and the Y-axis shows the genus. Negative values correspond to control; positive values correspond to cases. (<bold>D</bold>). Barplot of mean sqrt of relative abundance of taxa found by LEFSE. The X-axis shows the mean sqrt of relative abundance, and the Y-axis shows genus.</p></caption><graphic xlink:href="biotech-14-00031-g004" position="float"/></fig><table-wrap position="float" id="biotech-14-00031-t001"><object-id pub-id-type="pii">biotech-14-00031-t001_Table 1</object-id><label>Table 1</label><caption><p>General data for participants of the study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Control</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Number</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.92 (&#x000b1;7.67) (38)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.31 (&#x000b1;10.22) (51)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Menarche Age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.53 (&#x000b1;1.59) (38)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.64 (&#x000b1;1.44) (51)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age Start Sexual Life</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.67 (&#x000b1;3.00) (36)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.62 (&#x000b1;2.89) (48)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contraceptive Method</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14/32 (43.75%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29/57 (50.88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tubal ligation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/32 (3.12%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/57 (14.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Condom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/32 (18.75%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/57 (17.54%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intrauterine device</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/32 (6.25%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/57 (10.53%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/32 (21.88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/57 (7.02%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Implant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/32 (6.25%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/57 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Menstrual Cycle Phase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Luteal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19/32 (59.38%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32/55 (58.18%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follicular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/32 (34.38%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/55 (30.91%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovulation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/32 (6.25%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/55 (10.91%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex Partners</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15/32 (46.88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/54 (38.89%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm8" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/32 (53.13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33/54 (61.11%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gestations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/31 (54.84%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/52 (32.69%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/31 (22.58%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18/52 (34.62%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm9" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/31 (22.58%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/52 (32.69%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delivers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22/31 (70.97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32/52 (61.54%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/31 (12.90%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/52 (25.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm10" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/31 (16.13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/52 (13.46%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cesarean sections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25/31 (80.65%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30/52 (57.69%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/31 (16.13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/52 (40.38%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm11" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/31 (3.23%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/52 (1.92%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abortions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29/31 (93.54%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39/52 (75.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/31 (3.22%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12/52 (23.07%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm12" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/31 (3.22%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/52 (1.92%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mean pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.48 &#x000b1; 0.57 (29)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.78 &#x000b1; 1.25 (43)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm13" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02264;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14/25 (56.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/40 (42.50%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm14" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/25 (44.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/40 (57.50%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk factors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smoking</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/42 (19.05%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19/58 (33.33%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/42 (30.95%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25/57 (43.86%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/33 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/57 (8.77%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vulvovaginal Candidiasis episodes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31/31 (100.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/52 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/31 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38/52 (73.08%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm15" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/31 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14/52 (26.92%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCR <italic toggle="yes">Candida</italic> detection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Candida albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27/30 (90.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/47 (36.17%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.93 &#x000d7; 10<sup>&#x02212;6</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Nakaseomyses glabratus *</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/30 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46/47 (97.87%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;2.2 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Saccharomyces cerevisiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27/30 (90.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45/47 (95.74%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6000</td></tr></tbody></table><table-wrap-foot><fn><p>The mean is accompanied by (&#x000b1;), representing the standard deviation. ( ) is the number of participants with available data. Categorical data are shown as proportions; percentages are enclosed in parentheses. For age, menarche age, the start of sexual life, and pH, a Student&#x02019;s <italic toggle="yes">t</italic>-test was applied. A two-proportion z-test was used for the PCR detection results. * Former <italic toggle="yes">Candida glabrata</italic>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>